Bioforce Nanosciences Holdings Total Liabilities Growth & History (BFNH)
Bioforce Nanosciences Holdings's total liabilities was $619,329 for fiscal 2025.
View full Bioforce Nanosciences Holdings company overviewBioforce Nanosciences Holdings annual total liabilities history
| Fiscal year | Period ended | Total liabilities | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $619,329 | −$1.7M | −73.10% |
| 2024 | 2024-12-31 | $2.3M | $482,586 | +26.52% |
| 2023 | 2023-12-31 | $1.8M | $471,857 | +35.00% |
| 2022 | 2022-12-31 | $1.3M | $475,003 | +54.41% |
| 2021 | 2021-12-31 | $873,008 | $473,235 | +118.38% |
| 2020 | 2020-12-31 | $399,773 | $388,186 | +3350.19% |
| 2019 | 2019-12-31 | $11,587 | $6,264 | +117.68% |
| 2018 | 2018-12-31 | $5,323 | −$7,383 | −58.11% |
| 2017 | 2017-12-31 | $12,706 | — | — |
Bioforce Nanosciences Holdings quarterly total liabilities
| Fiscal quarter | Period ended | Total liabilities | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $84,767 | −$300,161 | −77.98% |
| Q1 2026 | 2026-03-31 | $727,301 | $452,260 | +164.43% |
| Q4 2025 | 2025-12-31 | $619,329 | −$1.7M | −73.10% |
| Q3 2025 | 2025-09-30 | $500,722 | −$1.7M | −77.03% |
| Q2 2025 | 2025-06-30 | $384,928 | −$1.7M | −81.36% |
| Q1 2025 | 2025-03-31 | $275,041 | −$1.7M | −85.90% |
| Q4 2024 | 2024-12-31 | $2.3M | $482,586 | +26.52% |
| Q3 2024 | 2024-09-30 | $2.2M | $474,561 | +27.83% |
| Q2 2024 | 2024-06-30 | $2.1M | $473,208 | +29.73% |
| Q1 2024 | 2024-03-31 | $2.0M | $472,715 | +31.98% |
| Q4 2023 | 2023-12-31 | $1.8M | $471,857 | +35.00% |
| Q3 2023 | 2023-09-30 | $1.7M | $472,214 | +38.29% |
| Q2 2023 | 2023-06-30 | $1.6M | $472,582 | +42.22% |
| Q1 2023 | 2023-03-31 | $1.5M | $472,582 | +47.01% |
| Q4 2022 | 2022-12-31 | $1.3M | $475,003 | +54.41% |
| Q3 2022 | 2022-09-30 | $1.2M | $464,755 | +60.47% |
| Q2 2022 | 2022-06-30 | $1.1M | $464,578 | +70.96% |
| Q1 2022 | 2022-03-31 | $1.0M | $468,444 | +87.24% |
| Q4 2021 | 2021-12-31 | $873,008 | $473,235 | +118.38% |
| Q3 2021 | 2021-09-30 | $768,537 | $491,329 | +177.24% |
| Q2 2021 | 2021-06-30 | $654,707 | $492,468 | +303.54% |
| Q1 2021 | 2021-03-31 | $536,942 | $492,866 | +1118.22% |
| Q4 2020 | 2020-12-31 | $399,773 | $388,186 | +3350.19% |
| Q3 2020 | 2020-09-30 | $277,208 | $272,668 | +6005.90% |
| Q2 2020 | 2020-06-30 | $162,239 | $157,224 | +3135.07% |
| Q1 2020 | 2020-03-31 | $44,076 | $37,301 | +550.57% |
| Q4 2019 | 2019-12-31 | $11,587 | $6,264 | +117.68% |
| Q3 2019 | 2019-09-30 | $4,540 | −$925 | −16.93% |
| Q2 2019 | 2019-06-30 | $5,015 | — | — |
| Q1 2019 | 2019-03-31 | $6,775 | — | — |
| Q4 2018 | 2018-12-31 | $5,323 | −$7,383 | −58.11% |
| Q3 2018 | 2018-09-30 | $5,465 | — | — |
| Q4 2017 | 2017-12-31 | $12,706 | — | — |
Bioforce Nanosciences Holdings total liabilities trends
Over the last five fiscal years, Bioforce Nanosciences Holdings's total liabilities increased from $399,773 to $619,329, a change of $219,556. The latest reported quarter, Q2 2026, shows $84,767.
What total liabilities mean
Total liabilities are all obligations reported on a company’s balance sheet, including debt, accounts payable, accrued expenses, deferred revenue, lease liabilities, and other current and long-term obligations.
SEC-reported and calculated total liabilities
TickerStat uses total liabilities reported in company SEC filings when available. Otherwise, it calculates total liabilities as aligned total assets minus total equity for the same balance-sheet date. Total liabilities should not be confused with interest-bearing debt. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Bioforce Nanosciences Holdings source filings ↗